Achaogen's stock rockets after positive UTI drug trial results
Achaogen Inc.'s stock rocketed 51% toward a 1 1/2-year high in premarket trade Monday, after the biopharmaceutical company said a phase 3 trial of its treatment for urinary tract infections met its primary endpoints. The company said its lead product candidate, plazomicin, also showed a lower rate of mortality or serious disease-related complications when compared with colistin therapy. Achaogen said it plans to submit a New Drug Application with the Food and Drug Administration in the second half of 2017... Читать дальше...